Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides calories for metabolic processes, restoring blood glucose levels and reducing protein and fat catabolism. Sodium chloride maintains osmolarity and replaces sodium and chloride losses.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Parenteral source of carbohydrates and electrolytes,Treatment of fluid and electrolyte depletion,Maintenance fluid therapy,Correction of hypovolemia
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion. Adult: 500-1000 m L per dose at a rate of 2-6 m L/min, frequency dependent on fluid and electrolyte needs. Maximum 40 m L/kg/day.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Glucose half-life is approximately 1.5-2 hours in normal individuals, prolonged in renal impairment or diabetes. Sodium and chloride have no defined half-life as they are electrolytes; their elimination depends on renal function and hydration status.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose is metabolized via glycolysis and the citric acid cycle; insulin-dependent uptake. Sodium chloride is not metabolized; excreted renally.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: >99% of administered glucose is metabolized or excreted; sodium and chloride are excreted renally. In dextrose 5% and sodium chloride 0.2%, glucose undergoes metabolism to CO2 and water; excess is excreted renally. Sodium and chloride are almost entirely excreted renally with >90% reabsorption under normal conditions.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Glucose: negligible (<1%). Sodium and chloride: not protein bound.
Low protein binding; 0–11% bound, primarily to albumin.
Glucose: approximately 0.2-0.25 L/kg; distributes primarily in extracellular fluid. Sodium: 0.6-0.7 L/kg (total body water); chloride: similar. Clinical meaning: initial distribution reflects ECF volume; changes indicate fluid shifts.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100% for all components. Not applicable for oral or other routes as this formulation is for IV use only.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
For GFR 30-50 m L/min: close monitoring of electrolytes; GFR <30 m L/min: use with caution, monitor for hypernatremia and fluid overload, reduce infusion rate by 50%.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific adjustment required for Child-Pugh class A or B; use with caution in class C due to risk of fluid overload.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Intravenous infusion. 5-10 m L/kg per dose as needed; rate not to exceed 0.5-1 g/kg/hour of dextrose. For neonates, avoid unless specific indication due to high sodium load.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Reduce initial infusion rate to 1-2 m L/min due to decreased renal function and higher risk of fluid overload; monitor serum sodium and osmolality closely.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Solutions containing dextrose may be contraindicated in patients with known allergies to corn or corn products. Intrathecal administration is contraindicated.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of hyperglycemia and hyperosmolar syndrome, especially in patients with diabetes mellitus,May cause fluid and solute overload leading to dilution of serum electrolytes, overhydration, congested states, or pulmonary edema,Use with caution in patients with heart failure, renal impairment, or severe dehydration,Not for use in patients with intracranial or intraspinal hemorrhage,Air embolism risk if administered via pressurized IV lines
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperglycemia and hyperosmolar coma,Hypersensitivity to corn or corn products,Intrathecal administration,Severe dehydration with hypernatremia,Addison's disease without adequate corticosteroid therapy
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions. Monitor fluid and electrolyte balance especially if patient is on a low-sodium diet. Dextrose may affect blood glucose; adjust meal timing or insulin accordingly.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Dextrose and sodium chloride are physiologic substances. No teratogenic risk is reported; however, hyperglycemia or electrolyte imbalances in the mother may affect the fetus. Use standard precautions.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Dextrose and sodium chloride are normal blood constituents; transfer into breast milk is not clinically significant. No M/P ratio available; considered safe during breastfeeding.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Total body water increases in pregnancy, potentially expanding distribution volume; however, dosing is based on clinical status. Monitor for fluid overload and electrolyte disturbances. No specific dose adjustment is required for standard maintenance infusions.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
This isotonic solution provides 170 kcal/L from dextrose and is used for maintenance hydration and electrolyte replacement. Monitor serum glucose in diabetics; may cause hyperglycemia. Contains 34 m Eq/L sodium and 34 m Eq/L chloride. Avoid in patients with hypernatremia, fluid overload, or significant renal impairment. Use with caution in pediatric and elderly patients due to risk of hyponatremia.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This solution provides sugar and salt to help maintain body fluids and energy.,Tell your healthcare provider if you have diabetes, heart failure, kidney disease, or are on a low-salt diet.,Report any swelling, shortness of breath, headache, nausea, or changes in urination.,Do not drink this solution; it is given intravenously.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides calories for metabolic processes, restoring blood glucose levels and reducing protein and fat catabolism. Sodium chloride maintains osmolarity and replaces sodium and chloride losses.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion. Adult: 500-1000 m L per dose at a rate of 2-6 m L/min, frequency dependent on fluid and electrolyte needs. Maximum 40 m L/kg/day.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride are physiologic substances. No teratogenic risk is reported; however, hyperglycemia or electrolyte imbalances in the mother may affect the fetus. Use s. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.